当前位置: 首页 >> 检索结果
2941. Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage.
作者: M A Sloan.;C A Sila.;K W Mahaffey.;C B Granger.;W T Longstreth.;P Koudstaal.;H D White.;J M Gore.;M L Simoons.;W D Weaver.;C L Green.;E J Topol.;R M Califf.
来源: Circulation. 1998年98卷14期1376-82页
Limited information exists on risk factors for mortality after thrombolysis-related intracranial hemorrhage. We wished to determine the characteristics associated with 30-day mortality after thrombolysis-related intracranial hemorrhage.
2942. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours preceding coronary intervention through 1 hour after intervention. To investigate the incidence of recurrent ischemia and the ischemic burden, a subset of 332 patients (26%) underwent continuous vector-derived 12-lead ECG-ischemia monitoring.
2943. Atrioventricular conduction during long-term follow-up of patients with sick sinus syndrome.
作者: H R Andersen.;J C Nielsen.;P E Thomsen.;L Thuesen.;T Vesterlund.;A K Pedersen.;P T Mortensen.
来源: Circulation. 1998年98卷13期1315-21页
It has been claimed that patients with sick sinus syndrome have an increased risk of developing AV block, but this has never been assessed prospectively. The aim of the present study was to evaluate in a prospective trial AV conduction during the long-term follow-up of patients with sick sinus syndrome.
2944. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI).
作者: A K Jacobs.;S F Kelsey.;M M Brooks.;D P Faxon.;B R Chaitman.;V Bittner.;M B Mock.;B H Weiner.;L Dean.;C Winston.;L Drew.;G Sopko.
来源: Circulation. 1998年98卷13期1279-85页
Numerous studies have shown that women undergoing coronary revascularization procedures do so at a higher risk for an adverse outcome compared with men. However, the impact of advances in technology and improvements in techniques on in-hospital and long-term outcome after revascularization in women is unclear.
2945. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
作者: D J Kereiakes.;N S Kleiman.;J J Ferguson.;A R Masud.;T M Broderick.;C W Abbottsmith.;J P Runyon.;L C Anderson.;R J Anders.;R J Dreiling.;G L Hantsbarger.;B Bryzinski.;E J Topol.
来源: Circulation. 1998年98卷13期1268-78页
Parenteral administration of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor blockers can reduce ischemic complications of coronary angioplasty. Orally active GP IIb/IIIa blockers may allow more sustained receptor antagonism with the potential for long-term secondary prevention. The pharmacodynamic efficacy, clinical safety, and outcomes after prolonged receptor blockade with an orally active GP IIb/IIIa antagonist are not known. The Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis (ORBIT) Trial is a multicenter, placebo-controlled, randomized trial of xemilofiban, an oral platelet GP IIb/IIIa blocking agent, administered to patients after percutaneous coronary intervention.
2946. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women.
作者: M Gerhard.;B W Walsh.;A Tawakol.;E A Haley.;S J Creager.;E W Seely.;P Ganz.;M A Creager.
来源: Circulation. 1998年98卷12期1158-63页
Epidemiological studies indicate that estrogen replacement therapy decreases the risk of cardiovascular events in postmenopausal women. Estrogen may confer cardiovascular protection by improving endothelial function because it increases endothelium-dependent vasodilation. It is not known whether progesterone attenuates the beneficial effects of estrogen on endothelial function.
2947. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
作者: P M Ridker.;N Rifai.;M A Pfeffer.;F M Sacks.;L A Moye.;S Goldman.;G C Flaker.;E Braunwald.
来源: Circulation. 1998年98卷9期839-44页
We studied whether inflammation after myocardial infarction (MI) is a risk factor for recurrent coronary events and whether randomized treatment with pravastatin reduces that risk.
2948. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study.
作者: M Brignole.;C Menozzi.;L Gianfranchi.;G Musso.;R Mureddu.;N Bottoni.;G Lolli.
来源: Circulation. 1998年98卷10期953-60页
Uncontrolled studies have suggested that atrioventricular junction ablation and pacemaker implantation have beneficial effects on quality of life in patients with chronic atrial fibrillation (AF).
2949. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Patients with acute ischemic syndromes (AIS) suffer high rates of recurrent ischemic events despite aspirin treatment. Long-term therapy with oral anticoagulants in addition to aspirin may reduce this risk. We studied the effects of long-term warfarin at 2 intensities in patients with AIS without ST elevation in 2 consecutive randomized controlled studies.
2950. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial.
作者: C Spaulding.;B Charbonnier.;A Cohen-Solal.;Y Juillière.;E P Kromer.;K Benhamda.;R Cador.;S Weber.
来源: Circulation. 1998年98卷8期757-65页
Coprescription of aspirin and ACE inhibitors is frequent in heart failure caused by coronary artery disease. Negative interaction between aspirin and enalapril has been reported, presumably through inhibition by aspirin of ACE inhibitor-induced prostaglandin synthesis. Ticlopidine is a potent antiplatelet agent without interaction with prostaglandin synthesis.
2951. Randomized, double-blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise-induced myocardial stunning.
作者: C A Rinaldi.;A Z Linka.;N D Masani.;P G Avery.;E Jones.;H Saunders.;R J Hall.
来源: Circulation. 1998年98卷8期749-56页
Myocardial stunning may cause prolonged left ventricular dysfunction after exercise-induced ischemia that can be attenuated by calcium antagonists in animal models. To assess their effects in humans, we performed a randomized, double-blind crossover study comparing the calcium antagonist amlodipine (10 mg once daily) versus isosorbide mononitrate (ISMN, 50 mg once daily) on postexercise stunning.
2952. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
作者: S J Brener.;L A Barr.;J E Burchenal.;S Katz.;B S George.;A A Jones.;E D Cohen.;P C Gainey.;H J White.;H B Cheek.;J W Moses.;D J Moliterno.;M B Effron.;E J Topol.
来源: Circulation. 1998年98卷8期734-41页
The benefit of catheter-based reperfusion for acute myocardial infarction (MI) is limited by a 5% to 15% incidence of in-hospital major ischemic events, usually caused by infarct artery reocclusion, and a 20% to 40% need for repeat percutaneous or surgical revascularization. Platelets play a key role in the process of early infarct artery reocclusion, but inhibition of aggregation via the glycoprotein IIb/IIIa receptor has not been prospectively evaluated in the setting of acute MI.
2953. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. This prospective, randomized, placebo-controlled, parallel-group clinical trial evaluated the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication.
2954. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
作者: G Montalescot.;F Philippe.;A Ankri.;E Vicaut.;E Bearez.;J E Poulard.;D Carrie.;D Flammang.;A Dutoit.;A Carayon.;C Jardel.;M Chevrot.;J P Bastard.;F Bigonzi.;D Thomas.
来源: Circulation. 1998年98卷4期294-9页
The pathogenesis of unstable angina and non-Q-wave myocardial infarction is still poorly understood, and early evaluation of prognosis remains difficult. We therefore studied the predictive value of 5 biological indicators of inflammation, thrombogenesis, vasoconstriction, and myocardial necrosis, and we examined the effects of enoxaparin and unfractionated heparin on these markers after 48 hours of treatment.
2955. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study.
作者: S John.;M Schlaich.;M Langenfeld.;H Weihprecht.;G Schmitz.;G Weidinger.;R E Schmieder.
来源: Circulation. 1998年98卷3期211-6页
Impaired endothelium-dependent vasodilation is an early sign of atherosclerosis in hypercholesterolemic patients. We hypothesized that lipid-lowering therapy can improve endothelial function and that this effect is mainly mediated by increased bioavailability of nitric oxide (NO).
2956. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents.
作者: J S Gottdiener.;D J Reda.;D W Williams.;B J Materson.;W Cushman.;R J Anderson.
来源: Circulation. 1998年98卷2期140-8页
Cardiac effects of hypertension include increased left ventricular (LV) mass and LV hypertrophy, as well as increased left atrial size, a predictor of stroke and atrial fibrillation. Although literature on reduction of LV mass with antihypertensive therapy is extensive, little information is available on effects of treatment on left atrial size.
2957. Dopamine depresses minute ventilation in patients with heart failure.
Low-dose dopamine is frequently used in patients in the intensive care setting. Dopamine may inhibit chemoreceptor afferents and hence decrease chemoreflex sensitivity to hypoxia.
2958. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction.
作者: H Suryapranata.;A W van 't Hof.;J C Hoorntje.;M J de Boer.;F Zijlstra.
来源: Circulation. 1998年97卷25期2502-5页
Although the benefits of primary angioplasty in acute myocardial infarction have been demonstrated, several areas for improvement remain. Therefore, a prospective randomized trial comparing primary stenting with balloon angioplasty in patients with acute myocardial infarction was conducted.
2959. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
来源: Circulation. 1998年97卷24期2386-95页
Unstable angina and non-Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation.
2960. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.
作者: W C Yu.;S A Chen.;S H Lee.;C T Tai.;A N Feng.;B I Kuo.;Y A Ding.;M S Chang.
来源: Circulation. 1998年97卷23期2331-7页
Atrial fibrillation (AF) has been shown to shorten the atrial effective refractory period (ERP) and make the atrium more vulnerable to AF. This study investigated the effect of atrial rate and antiarrhythmic drugs on ERP shortening induced by tachycardia.
|